Brian M Wolpin

List of Publications by Year
in descending order

87 papers	7,936 citations	76326 40 h-index	64796 79 g-index
87 all docs	87 docs citations	87 times ranked	13017 citing authors

#	Article	IF	Citations
1	Patterns of Adjuvant Chemotherapy Use and Association With Survival in Adults 80 Years and Older With Pancreatic Adenocarcinoma. JAMA Oncology, 2022, 8, 88.	7.1	11
2	A phase 1b study evaluating IL-1Î² and PD-1 targeting with chemotherapy in metastatic pancreatic cancer (PanCAN-SR1).. Journal of Clinical Oncology, 2022, 40, 557-557.	1.6	2
3	Surveillance Imaging in Individuals at High Risk for Pancreatic Cancer: Not a Ceiling, but Rather a Floor Upon Which to Build. Gastroenterology, 2022, 162, 700-702.	1.3	5
4	G-CSF-induced carotid inflammation. Lancet Oncology, The, 2022, 23, e235.	10.7	1
5	Physical activity in older adults with metastatic gastrointestinal cancer: a pilot and feasibility study. BMJ Open Sport and Exercise Medicine, 2022, 8, e001353.	2.9	2
6	Initial efficacy and biomarker analysis of a phase 1b study targeting IL-1Î² and PD-1 with chemotherapy in metastatic pancreatic cancer (PanCAN-SR1).. Journal of Clinical Oncology, 2022, 40, e16287-e16287.	1.6	0
7	Population-Scale CT-based Body Composition Analysis of a Large Outpatient Population Using Deep Learning to Derive Age-, Sex-, and Race-specific Reference Curves. Radiology, 2021, 298, 319-329.	7.3	80
8	Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. Gastroenterology, 2021, 160, 1373-1383.e6.	1.3	77
9	A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. Genome Medicine, 2021, 13, 15.	8.2	15
10	Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3. Cancer Research, 2021, 81, 3134-3143.	0.9	8
11	Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. Cancer Discovery, 2021, 11, 2014-2031.	9.4	79
12	Identification and management of pathogenic mutations in BRCA1, BRCA2, and PALB2 in a tumor-only genomic testing program.. Journal of Clinical Oncology, 2021, 39, 10528-10528.	1.6	1
13	Acquired Resistance to KRAS^{G12C} Inhibition in Cancer. New England Journal of Medicine, 2021, 384, 2382-2393.	27.0	482
14	Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Clinical Cancer Research, 2021, 27, 4574-4586.	7.0	82
15	Hepcidin-regulating iron metabolism genes and pancreatic ductal adenocarcinoma: a pathway analysis of genome-wide association studies. American Journal of Clinical Nutrition, 2021, 114, 1408-1417.	4.7	9
16	Abstract CT005: T cell inflammation in the tumor microenvironment after agonist CD40 antibody: Clinical and translational results of a neoadjuvant clinical trial. , 2021, , .		0
17	Beyond the Front Line: Emerging Data for Maintenance Therapy in Pancreatic Cancer. Journal of Clinical Oncology, 2021, 39, 3199-3206.	1.6	5
18	Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies. JCO Precision Oncology, 2021, 5, 1325-1338.	3.0	14

#	Article	IF	Citations
19	A 584Âbp deletion in CTRB2 inhibits chymotrypsin B2 activity and secretion and confers risk of pancreatic cancer. American Journal of Human Genetics, 2021, 108, 1852-1865.	6.2	15
20	Low glycaemic diets alter lipid metabolism to influence tumour growth. Nature, 2021, 599, 302-307.	27.8	142
21	Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Cell, 2021, 184, 6119-6137.e26.	28.9	201
22	Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. Investigational New Drugs, 2020, 38, 800-811.	2.6	106
23	Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. Cancer Discovery, 2020, 10, 104-123.	9.4	131
24	A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. Journal of the National Cancer Institute, 2020, 112, 1003-1012.	6.3	59
25	A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer. Investigational New Drugs, 2020, 38, 1533-1539.	2.6	13
26	Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma Exhibit Differential Growth and Metabolic Patterns in the Pre-Diagnostic Period: Implications for Early Detection. Frontiers in Oncology, 2020, 10, 596931.	2.8	10
27	Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2735-2739.	2.5	6
28	Multiplexed single-cell transcriptional response profiling to define cancer vulnerabilities and therapeutic mechanism of action. Nature Communications, 2020, 11, 4296.	12.8	98
29	Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q. Cell Reports, 2020, 33, 108493.	6.4	28
30	Genetic and Circulating Biomarker Data Improve Risk Prediction for Pancreatic Cancer in the General Population. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 999-1008.	2.5	19
31	The Mediterranean diet, plasma metabolome, and cardiovascular disease risk. European Heart Journal, 2020, 41, 2645-2656.	2.2	138
32	Genome-Wide Geneâ€"Diabetes and Geneâ€"Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1784-1791.	2.5	5
33	Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. Cancer Cell, 2020, 38, 198-211.e8.	16.8	99
34	Discovery of a selective inhibitor of doublecortin like kinase 1. Nature Chemical Biology, 2020, 16, 635-643.	8.0	84
35	Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk. Cancer Research, 2020, 80, 4004-4013.	0.9	5
36	Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. Nature Communications, 2020, 11, 3353.	12.8	75

#	Article	IF	Citations
37	Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma. Cell, 2020, 181, 832-847.e18.	28.9	77
38	BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nature Medicine, 2020, 26, 878-885.	30.7	297
39	Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance). Journal of the National Cancer Institute, 2019, 111, 170-179.	6.3	19
40	Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer. Journal of the National Cancer Institute, 2019, 111, 557-567.	6.3	21
41	Testing for Verification Bias in Reported Malignancy Risks for Side-Branch Intraductal Papillary Mucinous Neoplasms: A Simulation Modeling Approach. American Journal of Roentgenology, 2019, 212, 596-601.	2.2	4
42	Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Nature Communications, 2018, 9, 556.	12.8	188
43	Characterising cis-regulatory variation in the transcriptome of histologically normal and tumour-derived pancreatic tissues. Gut, 2018, 67, 521-533.	12.1	26
44	Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discovery, 2018, 8, 1096-1111.	9.4	256
45	When, What, and Why of Perioperative Treatment of Potentially Curable Pancreatic Adenocarcinoma. Journal of Clinical Oncology, 2017, 35, 485-489.	1.6	9
46	Leucocyte telomere length, genetic variants at theTERTgene region and risk of pancreatic cancer. Gut, 2017, 66, 1116-1122.	12.1	39
47	Functional characterization of a multi-cancer risk locus on chr5p15.33 reveals regulation of TERT by ZNF148. Nature Communications, 2017, 8, 15034.	12.8	40
48	Covariate selection for association screening in multiphenotype genetic studies. Nature Genetics, 2017, 49, 1789-1795.	21.4	27
49	Critical role for arginase 2 in obesity-associated pancreatic cancer. Nature Communications, 2017, 8, 242.	12.8	67
50	Quantifying the Genetic Correlation between Multiple Cancer Types. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1427-1435.	2.5	48
51	Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature, 2017, 547, 453-457.	27.8	1,194
52	Reply to A. Braillon. Journal of Clinical Oncology, 2017, 35, 1136-1137.	1.6	0
53	Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. Oncotarget, 2016, 7, 66328-66343.	1.8	88
54	Association of Common Susceptibility Variants of Pancreatic Cancer in Higher-Risk Patients: A PACGENE Study. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1185-1191.	2.5	29

#	Article	IF	Citations
55	Functional characterization of a chr13q22.1 pancreatic cancer risk locus reveals long-range interaction and allele-specific effects onDIS3expression. Human Molecular Genetics, 2016, 25, ddw300.	2.9	24
56	Pancreatic Cancer Risk Associated with Prediagnostic Plasma Levels of Leptin and Leptin Receptor Genetic Polymorphisms. Cancer Research, 2016, 76, 7160-7167.	0.9	46
57	Circulating Exosomes in Pancreatic Cancer: Will They Succeed on the Long, Littered Road to Early Detection Marker?. Clinical Chemistry, 2016, 62, 307-309.	3.2	17
58	Winner's Curse Correction and Variable Thresholding Improve Performance of Polygenic Risk Modeling Based on Genome-Wide Association Study Summary-Level Data. PLoS Genetics, 2016, 12, e1006493.	3.5	98
59	<scp>TERT</scp> gene harbors multiple variants associated with pancreatic cancer susceptibility. International Journal of Cancer, 2015, 137, 2175-2183.	5.1	57
60	Characterization of Large Structural Genetic Mosaicism in Human Autosomes. American Journal of Human Genetics, 2015, 96, 487-497.	6.2	101
61	Pancreatic Cancer. Hematology/Oncology Clinics of North America, 2015, 29, xiii-xiv.	2.2	10
62	Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma. Hematology/Oncology Clinics of North America, 2015, 29, 761-776.	2.2	11
63	Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Nature Genetics, 2015, 47, 911-916.	21.4	224
64	Reply to Y. Mao et al. Journal of Clinical Oncology, 2015, 33, 2121-2122.	1.6	0
65	Identification of the Metabolomic Fingerprint Associated with Flavonoid Consumption Level. FASEB Journal, 2015, 29, 745.7.	0.5	0
66	Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma. Oncologist, 2014, 19, 637-638.	3.7	292
67	Variants Associated with Susceptibility to Pancreatic Cancer and Melanoma Do Not Reciprocally Affect Risk. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1121-1124.	2.5	14
68	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Human Molecular Genetics, 2014, 23, 6616-6633.	2.9	90
69	Managing Advanced Colorectal Cancer: Have We Reached the PEAK With Current Therapies?. Journal of Clinical Oncology, 2014, 32, 2200-2202.	1.6	6
70	Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local control. Practical Radiation Oncology, 2014, 4, e117-e123.	2.1	4
71	Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Nature Genetics, 2014, 46, 994-1000.	21.4	294
72	Hyperglycemia, Insulin Resistance, Impaired Pancreatic Î²-Cell Function, and Risk of Pancreatic Cancer. Journal of the National Cancer Institute, 2013, 105, 1027-1035.	6.3	146

#	Article	IF	Citations
73	Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer. Oncologist, 2013, 18, 377-378.	3.7	40
74	Plasma 25-Hydroxyvitamin D and Risk of Pancreatic Cancer. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 82-91.	2.5	97
75	A phase I study of temsirolimus in combination with gemcitabine in previously untreated metastatic pancreatic cancer.. Journal of Clinical Oncology, 2012, 30, 296-296.	1.6	2
76	Immediate versus delayed adjuvant chemoradiation for resected pancreatic cancer: An analysis of local control and survival.. Journal of Clinical Oncology, 2012, 30, 301-301.	1.6	0
77	Feasibility of computer-based self-administered cancer-specific geriatric assessment (SA-CSGA) in older pts with gastrointestinal malignancy (GIM).. Journal of Clinical Oncology, 2012, 30, e19586-e19586.	1.6	0
78	Variant ABO Blood Group Alleles, Secretor Status, and Risk of Pancreatic Cancer: Results from the Pancreatic Cancer Cohort Consortium. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 3140-3149.	2.5	78
79	Pancreatic Cancer Risk and ABO Blood Group Alleles: Results from the Pancreatic Cancer Cohort Consortium. Cancer Research, 2010, 70, 1015-1023.	0.9	203
80	ABO Blood Group and the Risk of Pancreatic Cancer. Journal of the National Cancer Institute, 2009, 101, 424-431.	6.3	321
81	Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer. Journal of Clinical Oncology, 2009, 27, 193-198.	1.6	275
82	The Writing on the Wall. New England Journal of Medicine, 2009, 361, 1387-1392.	27.0	5
83	Insulin, the Insulin-Like Growth Factor Axis, and Mortality in Patients With Nonmetastatic Colorectal Cancer. Journal of Clinical Oncology, 2009, 27, 176-185.	1.6	208
84	Systemic Treatment of Colorectal Cancer. Gastroenterology, 2008, 134, 1296-1310.e1.	1.3	418
85	Circulating Insulin-Like Growth Factor Binding Protein-1 and the Risk of Pancreatic Cancer. Cancer Research, 2007, 67, 7923-7928.	0.9	71
86	Adjuvant Treatment of Colorectal Cancer. Ca-A Cancer Journal for Clinicians, 2007, 57, 168-185.	329.8	227
87	Phase I Study of Gefitinib plus FOLFIRI in Previously Untreated Patients with Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2006, 6, 208-213.	2.3	21